Residual Viremia and Viral Reservoirs in Elite Controllers

Robert W. Buckheit, Joel N Blankson

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Clinical outcome of human immunodeficiency virus 1 (HIV-1) infection varies greatly between infected individuals. Elite controllers (ECs) are HIV-1-infected individuals who maintain viral loads of less than 50 copies/milliliter in the absence of antiretroviral treatment. ECs are seen to have a lower proportion of latently infected cells, due to low magnitude of peak viremia seen in acute infection. Continued viral evolutions are observed in residual viremia from ECs, suggesting ongoing replication that continues in patients. This indicates that even while ECs are able to maintain low viral loads (VLs), beginning early in infection, a fully pathogenic virus continues to persist in these patients at low levels. In addition, HIV-1 infection is typically characterized by peak VLs in acute infection. Viral replication continues at high levels in the absence of therapy, and progressive CD4 + T cells decline, and acquired immune deficiency syndrome (AIDS) usually develops within 10 years after initial infection.

Original languageEnglish (US)
Title of host publicationModels of Protection Against HIV/SIV
PublisherElsevier Inc.
Pages253-271
Number of pages19
ISBN (Print)9780123877154
DOIs
StatePublished - 2012

Fingerprint

Viremia
Viruses
Viral Load
HIV-1
Controllers
Virus Diseases
Infection
T-cells
Acquired Immunodeficiency Syndrome
T-Lymphocytes
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Buckheit, R. W., & Blankson, J. N. (2012). Residual Viremia and Viral Reservoirs in Elite Controllers. In Models of Protection Against HIV/SIV (pp. 253-271). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-387715-4.00009-5

Residual Viremia and Viral Reservoirs in Elite Controllers. / Buckheit, Robert W.; Blankson, Joel N.

Models of Protection Against HIV/SIV. Elsevier Inc., 2012. p. 253-271.

Research output: Chapter in Book/Report/Conference proceedingChapter

Buckheit, RW & Blankson, JN 2012, Residual Viremia and Viral Reservoirs in Elite Controllers. in Models of Protection Against HIV/SIV. Elsevier Inc., pp. 253-271. https://doi.org/10.1016/B978-0-12-387715-4.00009-5
Buckheit RW, Blankson JN. Residual Viremia and Viral Reservoirs in Elite Controllers. In Models of Protection Against HIV/SIV. Elsevier Inc. 2012. p. 253-271 https://doi.org/10.1016/B978-0-12-387715-4.00009-5
Buckheit, Robert W. ; Blankson, Joel N. / Residual Viremia and Viral Reservoirs in Elite Controllers. Models of Protection Against HIV/SIV. Elsevier Inc., 2012. pp. 253-271
@inbook{6be5d3dc2ca34890b7b4cf96adeaf3af,
title = "Residual Viremia and Viral Reservoirs in Elite Controllers",
abstract = "Clinical outcome of human immunodeficiency virus 1 (HIV-1) infection varies greatly between infected individuals. Elite controllers (ECs) are HIV-1-infected individuals who maintain viral loads of less than 50 copies/milliliter in the absence of antiretroviral treatment. ECs are seen to have a lower proportion of latently infected cells, due to low magnitude of peak viremia seen in acute infection. Continued viral evolutions are observed in residual viremia from ECs, suggesting ongoing replication that continues in patients. This indicates that even while ECs are able to maintain low viral loads (VLs), beginning early in infection, a fully pathogenic virus continues to persist in these patients at low levels. In addition, HIV-1 infection is typically characterized by peak VLs in acute infection. Viral replication continues at high levels in the absence of therapy, and progressive CD4 + T cells decline, and acquired immune deficiency syndrome (AIDS) usually develops within 10 years after initial infection.",
author = "Buckheit, {Robert W.} and Blankson, {Joel N}",
year = "2012",
doi = "10.1016/B978-0-12-387715-4.00009-5",
language = "English (US)",
isbn = "9780123877154",
pages = "253--271",
booktitle = "Models of Protection Against HIV/SIV",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Residual Viremia and Viral Reservoirs in Elite Controllers

AU - Buckheit, Robert W.

AU - Blankson, Joel N

PY - 2012

Y1 - 2012

N2 - Clinical outcome of human immunodeficiency virus 1 (HIV-1) infection varies greatly between infected individuals. Elite controllers (ECs) are HIV-1-infected individuals who maintain viral loads of less than 50 copies/milliliter in the absence of antiretroviral treatment. ECs are seen to have a lower proportion of latently infected cells, due to low magnitude of peak viremia seen in acute infection. Continued viral evolutions are observed in residual viremia from ECs, suggesting ongoing replication that continues in patients. This indicates that even while ECs are able to maintain low viral loads (VLs), beginning early in infection, a fully pathogenic virus continues to persist in these patients at low levels. In addition, HIV-1 infection is typically characterized by peak VLs in acute infection. Viral replication continues at high levels in the absence of therapy, and progressive CD4 + T cells decline, and acquired immune deficiency syndrome (AIDS) usually develops within 10 years after initial infection.

AB - Clinical outcome of human immunodeficiency virus 1 (HIV-1) infection varies greatly between infected individuals. Elite controllers (ECs) are HIV-1-infected individuals who maintain viral loads of less than 50 copies/milliliter in the absence of antiretroviral treatment. ECs are seen to have a lower proportion of latently infected cells, due to low magnitude of peak viremia seen in acute infection. Continued viral evolutions are observed in residual viremia from ECs, suggesting ongoing replication that continues in patients. This indicates that even while ECs are able to maintain low viral loads (VLs), beginning early in infection, a fully pathogenic virus continues to persist in these patients at low levels. In addition, HIV-1 infection is typically characterized by peak VLs in acute infection. Viral replication continues at high levels in the absence of therapy, and progressive CD4 + T cells decline, and acquired immune deficiency syndrome (AIDS) usually develops within 10 years after initial infection.

UR - http://www.scopus.com/inward/record.url?scp=84882876443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882876443&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-387715-4.00009-5

DO - 10.1016/B978-0-12-387715-4.00009-5

M3 - Chapter

AN - SCOPUS:84882876443

SN - 9780123877154

SP - 253

EP - 271

BT - Models of Protection Against HIV/SIV

PB - Elsevier Inc.

ER -